Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.47 |
| ▸ | GRM5 | P41594 | 11/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061832 | 0.91 | PDK4 (0.52) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL31283668 | 0.88 | PDK4 (0.52) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL15376949 | 0.88 | PDK4 (0.50) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL28668463 | 0.83 | PDK4 (0.54) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL24669280 | 0.83 | NAMPT (0.62) | PDK4NAMPTGRM1GRM5JAK1 | |
| SCHEMBL19703165 | 0.82 | PDK4 (0.53) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL30779416 | 0.81 | PDK4 (0.52) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL5223668 | 0.80 | NAMPT (0.49) | PDK4NAMPTGRM1GRM5HTR6 | |
| SCHEMBL23013306 | 0.80 | QDPR (0.43) | HTR6 | |
| SCHEMBL2951348 | 0.80 | NAMPT (0.60) | PDK4NAMPTGRM1GRM5HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142338-A1 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4110775-A1 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142338-A1 | THIOPHENYL DERIVATIVES USEFUL FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN3, NSUN2 | PDK4 2384/4885NAMPT 1626/4885GRM1 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.